Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin

International Journal of Pharmaceutics

Volumn 389, Issue 1-2, 2010, Pages 74-85

  Hamishehkar, Hamed ^a   Emami, Jaber ^b   Najafabadi, Abdolhossien Rouholamini ^c   Gilani, Kambiz ^c   Minaiyan, Mohsen ^b   Mahdavi, Hamid ^d   Nokhodchi, Ali ^e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN POLYMER AND PETROCHEMICAL INSTITUTE   (Iran)

^e MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Carrier; Dry powder inhalation; Insulin; Mannitol; Particle engineering; PLGA; Sorbitol

Indexed keywords

MANNITOL; RECOMBINANT HUMAN INSULIN; SORBITOL;

AEROSOL; ARTICLE; ATOMIC FORCE MICROSCOPY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; FLOW RATE; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHALER; MICROCAPSULE; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; EXCIPIENTS; FREEZE DRYING; INSULIN; LACTIC ACID; MANNITOL; PARTICLE SIZE; POLYGLYCOLIC ACID; SORBITOL;

EID: 77349091988     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.01.021     Document Type: Article

References (58)

1. Bhandari B.R., and Roos Y.H. Dissolution of sucrose crystals in the anhydrous sorbitol melt. Carbohyd. Res. 338 (2003) 361-367
2. Buckton G., and Darcy P. Assessment of disorder in crystalline powders-a review of analytical techniques and their application. Int. J. Pharm. 179 (1999) 141-158
3. Carpenter J.F., Pikal M.J., Chang B.S., and Randolph T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14 (1997) 969-975
4. Chan H.K., and Goada I. Aerodynamic properties of elongated particles of cromoglycic acid. J. Aerosol Sci. 20 (1989) 157-168
5. Chan L.W., Lim L.T., and Heng P.W.S. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations. J. Pharm. Sci. 92 (2003) 975-984
6. Chidavaenzi O.C., Buckton G., and Koosha F. The effect of co-spray drying with polyethylene glycol 4000 on the crystallinity and physical form of lactose. Int. J. Pharm. 216 (2001) 43-49
7. Courrier H.M., Butz N., and Vandamme T.F. Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 425-498
8. de Boer A.H., Hagedoorn P., Gjaltema D., Goede J., and Frijlink H.W. Air classifier technology (ACT) in dry powder inhalation. Part 1. Application of a Force Distribution Concept (FDC) to explain the performance of a basic classifier on adhesive mixtures. Int. J. Pharm. 260 (2003) 187-200
9. de Boer A.H., Hagedoorn P., Gjaltema D., Goede J., Kussendrager K.D., and Frijlink H.W. Air classifier technology (ACT) in dry powder inhalation. Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation. Int. J. Pharm. 260 (2003) 201-216
10. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., and Langer R. Large porous particles for pulmonary drug delivery. Science 276 (1997) 1868-1871
11. Emami J., Hamishehkar H., Najafabadi A.R., Gilani K., Minaiyan M., Mahdavi H., and Nokhodchi A. A novel approach to prepare insulin-loaded poly(lactic-co-glycolic acid) microcapsules and the protein stability study. J. Pharm. Sci. (2009) 1712-1731
12. Emami J., Hamishehkar H., Najafabadi A.R., Gilani K., Minaiyan M., Mahdavi H., Mirzadeh H., Fakhari A., and Nokhodchi A. Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J. Microencapsul. 26 (2009) 1-8
13. European Commission-Health & Consumer Protection Directorate, 2002. Provisional statement on the safety of calf-derived rennet for the manufacture of pharmaceutical grade lactose.
14. Flament M.P., Leterme P., and Gayot A. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. Int. J. Pharm. 275 (2004) 201-209
15. Fults K.A., Miller I.F., and Hickey A.J. Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm. Dev. Technol. 2 (1997) 67-79
16. Gilani K., Najafabadi A.R., Darabi M., Barghi M.A., and Rafiee-Tehrani M. Influence of formulation variables and inhalation device on the deposition profiles of cromolyn sodium dry powder aerosols. Daru 12 (2004) 123-130
17. Glasnapp A. Alternatives for the lactose-intolerant patient. Int. J. Pharm. Compd. 2 (1998) 412-413
18. Ganderton D., and Kassem N.M. Dry powder inhalers. Advances in Pharmaceutical Sciences vol. 6 (1992), Academic Press, London pp. 165-191
19. ® DPI. Eur. J. Pharm. Sci. 16 (2002) 313-321
20. Heng P.W.S., Chan L.W., and Lim L.T. Quantification of the surface morphologies of lactose carriers and their effect on the in vitro deposition of salbutamol sulphate. Chem. Pharm. Bull. 48 (2000) 393-398
21. Iida K., Hayakawa Y., Okamoto H., Danjo K., and Luenberger H. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Chem. Pharm. Bull. 49 (2001) 1326-1330
22. Iida K., Hayakawa Y., Okamoto H., Danjo K., and Luenberger H. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem. Pharm. Bull. 51 (2003) 1455-1457
23. Iida K., Hayakawa Y., Okamoto H., Danjo K., and Luenberger H. Preparation of dry powder inhalation by surface treatment of lactose carrier particles. Chem. Pharm. Bull. 51 (2003) 1-5
24. Iida K., Inagaki Y., Todo H., Okamoto H., Danjo K., and Luenberger H. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem. Pharm. Bull. 52 (2004) 938-942
25. Izutsu K.I., Yoshioka S., and Terao T. Decreased protein stabilizing effects of cryoprotectants due to crystallization. Pharm. Res. 10 (1993) 1232-1237
26. Kawashima Y., Serigano T., Hino T., Yamamoto H., and Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int. J. Pharm. 172 (1998) 179-188
27. Kaye B.H. A Random Walk Through Fractal Dimensions (1989), VCH Publishers, Weinheim
28. Langer R. Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Acc. Chem. Res. 33 (2000) 94-101
29. Larhrib H., Zeng X.M., Martin G.P., Marriott C., and Pritchard J. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int. J. Pharm. 191 (1999) 1-14
30. Louey M.D., Van Oort M., and Hickey A.J. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques. Pharm. Res. 21 (2004) 1200-1206
31. Lucas P., Anderson K., and Staniforth J.N. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm. Res. 15 (1998) 562-569
32. ® and its absorption in healthy volunteers. J. Control. Release 97 (2004) 19-29
33. Nash R.A. Sorbitol. In: Kibbe A.H. (Ed). Handbook of Pharmaceutical Excipients. third ed. (2000), Pharmaceutical Press, London 151-518
34. Patton J.S., and Platz R.M. Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8 (1992) 179-228
35. Pikal M.J., Lukes A.L., Lang J.E., and Gaines K. Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: correlations with stability. J. Pharm. Sci. 67 (1978) 767-772
36. Podczeck F. The relationship between physical properties of lactose monohydrate and the aerodynamic behavior of adhered drug particles. Int. J. Pharm. 160 (1998) 119-130
37. Podczeck F., Newton J.M., and James M.B. Variations in the adhesion force between a drug and carrier particles as a result of changes in the relative humidity of the air. Int. J. Pharm. 149 (1997) 151-160
38. Price R., and Young P.M. On the physical transformations of processed pharmaceutical solids. Micron 36 (2005) 519-524
39. Prime D., Atkins P.J., Slater A., and Sumby B. Review of dry powder inhalers. Adv. Drug Deliv. Rev. 26 (1997) 51-58
40. Saint-Lorant G., Leterme P., Gayot A., and Flament M.P. Influence of carrier on the performance of dry powder inhalers. Int. J. Pharm. 334 (2007) 85-91
41. Schiavone H., Palakodaty S., Clark A., and York P. Evaluation of SCF engineered particle-based lactose blends in passive dry powder inhalers. Int. J. Pharm. 281 (2004) 55-66
42. Seo J.A., Oh J., Kim H.K., and Hwang Y.H. Study of Glass Transition Temperatures in Sugar Mixtures. J. Korean Phys. Soc. 46 (2005) 606-609
43. Smyth H.D.C., and Hickey A.J. Carriers in drug powder delivery: implications for inhalation system design. Am. J. Drug Deliv. 3 (2005) 117-132
44. Steckel H., Markefka P., teWierik H., and Kammelar R. Functionality testing of inhalation grade lactose. Eur. J. Pharm. Biopharm. 57 (2004) 495-505
45. Steckel H., and Muller B.W. In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro deposition. Int. J. Pharm. 154 (1997) 31-37
46. Tee S.K., Marriott C., Zeng X.M., and Martin G.P. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int. J. Pharm. 208 (2000) 111-123
47. Telko M.J., and Hickey A.J. Dry powder inhaler formulation. Respir. Care 50 (2005) 1209-1227
48. Timsina M.P., Martin G.P., Marriott C., Ganderton D., and Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101 (1994) 1-13
49. Todo H., Okamoto H., Iida K., and Danjo K. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int. J. Pharm. 220 (2001) 101-110
50. Traini D., Young P.M., Jones M., Edge S., and Price R. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation. Eur. J. Pharm. Sci. 27 (2006) 243-251
51. Taylor M.K., Ginsburg J., Hickey A.J., and Gheyas F. Composite method to quantify powder flow as a screening method in early tablet or capsule formulation development. AAPS Pharm. Sci. Tech. 1 (2000) (article 18)
52. Ward G.H., and Schultz R.K. Processed-induced crystallinity changes in albuterol sulphate and its effect on powder physical stability. Pharm. Res. 12 (1995) 773-779
53. Young P.M., Cocconi D., Colombo P., Bettini R., Price R., Steele D.F., and Tobyn M.J. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing". J. Pharm. Pharmacol. 54 (2002) 1339-1344
54. Young P.M., and Price R. The influence of humidity on the aerolisation of micronised and SEDS produced salbutamol sulphate. Eur. J. Pharm. Sci. 22 (2004) 235-240
55. Yu L., Milton N., Groleau E.G., Mishra D.S., and Vansickle R.E. Existence of a mannitol hydrate during freeze-drying and practical implications. J. Pharm. Sci. 88 (1999) 196-198
56. Zeng X.M., Martin G.P., Marriott C., and Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int. J. Pharm. 200 (2000) 93-106
57. Zeng X.M., Martin G.P., Marriott C., and Pritchard J. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J. Pharm. Sci. 90 (2001) 1424-1434
58. Zeng X.M., Pandhal K.H., and Martin G.P. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int. J. Pharm. 197 (2000) 41-52